Johnathan C. Maher

Under normoxia, 2-deoxy-<scp>d</scp>-glucose elicits cell death in select tumor types not by inhibition of glycolysis but by interfering with N-linked glycosylation

Metin Kurtoğlu, Ningguo Gao, Jie Shang et al. · Molecular Cancer Therapeutics · 2007 · 244 citations

Life Sciences, Cell Biology, Oncology +17

Greater cell cycle inhibition and cytotoxicity induced by 2-deoxy-d-glucose in tumor cells treated under hypoxic vs aerobic conditions

Johnathan C. Maher, Awtar Krishan, Théodore J. Lampidis · Cancer Chemotherapy and Pharmacology · 2004 · 204 citations

Life Sciences, Cell Biology, Oncology +16

Hypoxia-inducible factor-1 confers resistance to the glycolytic inhibitor 2-deoxy-<scp>d</scp>-glucose

Johnathan C. Maher, Medhi Wangpaichitr, Niramol Savaraj et al. · Molecular Cancer Therapeutics · 2007 · 107 citations · Full text

Life Sciences, Cell Biology, Oncology +17

Sequencing of Sipuleucel-T and Androgen Deprivation Therapy in Men with Hormone-Sensitive Biochemically Recurrent Prostate Cancer: A Phase II Randomized Trial

Emmanuel S. Antonarakis, Adam S. Kibel, Evan Y. Yu et al. · Clinical Cancer Research · 2016 · 78 citations

Medicine, Oncology, Urology +17

Efficacy of 2-halogen substituted d-glucose analogs in blocking glycolysis and killing “hypoxic tumor cells”

Théodore J. Lampidis, Metin Kurtoğlu, Johnathan C. Maher et al. · Cancer Chemotherapy and Pharmacology · 2006 · 77 citations

Medicine, Oncology, Pharmacology +14